BCL2 and cancer: Nevertheless, despite the remarkable advances in targeting BCL-2 members for cancer therapy, a better understanding of mechanisms underlying cancer cells resistance to venetoclax as a single agent as well as in combination with other agents is needed for developing safe, effective, and durable treatments.